Search results for "bowel"

showing 10 items of 637 documents

Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis

2005

AIM: To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease (IBD) and to characterize the anti-inflammatory action of antithrombin III (ATIII) on leukocyte kinetics and liver damage. METHODS: Hepatic and intestinal microcirculation was investigated by intravital videomicroscopy. Standardized models of experimental chronic liver cirrhosis and bowel inflammation were employed. Animals were divided into four groups (n = 6/group): controls, animals with cirrhosis, animals with cirrhosis and IBD, animals with cirrhosis and IBD treated with ATIII. RESULTS: Cirrhosis facilitated leukocyte rolling and sticking in hepatic sinusoids…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSerine Proteinase InhibitorsAntithrombin IIIInflammationInflammatory bowel diseaseGastroenterologyMicrocirculationEnteritisInternal medicineMedicineAnimalsRats WistarLiver injurybusiness.industryMicrocirculationAntithrombinGastroenterologyGeneral MedicineBlood flowmedicine.diseasedigestive system diseasesEnteritisRatsIntestinesLiverBrief Reportsmedicine.symptombusinessmedicine.drug
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

ANALISI DEL RUOLO DI MEDIATORI ENTERICI NELLA FISIOPATOLOGIA DELLE MALATTIE INFIAMMATORIE CRONICHE INTESTINALI

MICI IBD Inflammatory Bowel Disease Enteric Nervous System Inflammation Gastrointestinal Angiotensin GABA
researchProduct

Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data

2019

Crohn Disease (CD) is a complex genetic disorder for which more than 140 genes have been identified using genome wide association studies (GWAS). However, the genetic architecture of the trait remains largely unknown. The recent development of machine learning (ML) approaches incited us to apply them to classify healthy and diseased people according to their genomic information. The Immunochip dataset containing 18,227 CD patients and 34,050 healthy controls enrolled and genotyped by the international Inflammatory Bowel Disease genetic consortium (IIBDGC) has been re-analyzed using a set of ML methods: penalized logistic regression (LR), gradient boosted trees (GBT) and artificial neural ne…

Male/692/4020/1503/257/1402GenotypeGenotyping TechniquesLOCI/45/43lcsh:MedicinePolymorphism Single NucleotideCrohn's disease genetics genome wide associationArticleDeep LearningCrohn DiseaseINDEL MutationGenetics researchHumansgeneticsGenetic Predisposition to Disease/129lcsh:ScienceAllelesScience & Technologygenome wide associationRISK PREDICTION/45Models Geneticlcsh:RDecision Trees/692/308/2056ASSOCIATIONMultidisciplinary SciencesCrohn's diseaseLogistic ModelsNonlinear DynamicsROC CurveArea Under CurveScience & Technology - Other Topicslcsh:QFemaleNeural Networks ComputerINFLAMMATORY-BOWEL-DISEASEGenome-Wide Association StudyScientific Reports
researchProduct

Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice

2018

AbstractPrevious studies have established that an increased Th-9 response creates a hostile environment for nematode parasites. Given that IL-23, a cytokine required for maintenance of the IL-17–secreting phenotype, has inhibitory effects on IL-9 production, we hypothesized that reducing circulating IL-23 by treatment with anti-IL-23 antibodies would reduce the establishment and development of parasitic intestinal nematodes. In this study, we show that animals treated with anti-IL-23 monoclonal antibodies showed a drastic reduction in the number of mouse pinworms (Aspiculuris tetraptera) recovered from the intestine (p < 0.001) at 23 days post-infection compared to the untreated animals.…

Male0301 basic medicineChemokinemedicine.drug_classmedicine.medical_treatmentlcsh:MedicineMonoclonal antibodyInterleukin-23Inflammatory bowel diseaseArticleParasite LoadMice03 medical and health sciencesInterleukin 23medicineAnimalsNematode Infectionslcsh:ScienceMice Inbred ICRMultidisciplinarybiologyInterleukinslcsh:RAntibodies Monoclonalmedicine.diseasebiology.organism_classificationIntestinesCCL20030104 developmental biologyNematodeCytokineImmunologybiology.proteinlcsh:QAntibodyInjections Intraperitoneal
researchProduct

PD123319, angiotensin II type II receptor antagonist, inhibits oxidative stress and inflammation in 2, 4-dinitrobenzene sulfonic acid-induced colitis…

2019

Angiotensin II, the main effector of renin angiotensin system, plays an important role in the inflammatory process and most of its effects are mediated through the AT1 receptor activation. However, the knowledge about the AT2 receptor involvement in this process is still evolving. We previously found that in an experimental model of colitis, AT2 receptor activation can contribute to the impairment of the muscle contractility in vitro in the course of inflammation. Here, we investigated the potential alleviating effects of the in vivo treatment of PD123319 (1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid ditriflu…

Male0301 basic medicineColonPyridinesmedicine.drug_classImmunologyAngiotensin II Type 2 Receptor BlockersPharmacologyAT2 receptorReceptor Angiotensin Type 2Inflammatory bowel diseaseInflammatory bowel diseaseProinflammatory cytokineContractility03 medical and health sciencesAngiotensin0302 clinical medicinemedicineAnimalsPharmacology (medical)Rats WistarColitisReceptorPharmacologyInflammationAngiotensin II receptor type 1ChemistryAngiotensin IIImidazolesColitismedicine.diseaseReceptor antagonistAngiotensin IIRatsDinitrobenzenesOxidative Stress030104 developmental biology030217 neurology & neurosurgery
researchProduct

Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer I…

2017

Background and aims An increased risk of small bowel carcinoma [SBC] has been reported in coeliac disease [CD] and Crohn's disease [CrD]. We explored clinico-pathological, molecular, and prognostic features of CD-associated SBC [CD-SBC] and CrD-associated SBC [CrD-SBC] in comparison with sporadic SBC [spo-SBC]. Methods A total of 76 patients undergoing surgical resection for non-familial SBC [26 CD-SBC, 25 CrD-SBC, 25 spo-SBC] were retrospectively enrolled to investigate patients' survival and histological and molecular features including microsatellite instability [MSI] and KRAS/NRAS, BRAF, PIK3CA, TP53, HER2 gene alterations. Results CD-SBC showed a significantly better sex-, age-, and st…

Male0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologySurvivalReceptor ErbB-2Colorectal cancermedicine.disease_causeInflammatory bowel diseaseInflammatory bowel diseasetumour-infiltrating lymphocyteErbB-20302 clinical medicineCrohn DiseaseRetrospective StudieRisk Factors80 and overChildClass I Phosphatidylinositol 3-KinaseAged 80 and overColonic NeoplasmSettore MED/12 - GastroenterologiaCrohn's diseaseMLH1 methylationTumour-infiltrating lymphocytesGastroenterologyGeneral MedicineMiddle AgedPrognosisInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Gastroenterology030220 oncology & carcinogenesisColonic NeoplasmsSurvival AnalysiKRASHumanReceptorAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognosiClass I Phosphatidylinositol 3-KinasesSettore MED/08 - Anatomia PatologicaNOProto-Oncogene Proteins p21(ras)MLH1 promoter methylationYoung Adult03 medical and health sciencesInternal medicinemedicineCarcinomaHumansMLH1 methylation; inflammatory bowel disease; microsatellite instability; survival; tumour-infiltrating lymphocytesneoplasmsAgedRetrospective StudiesInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Adult; Aged; Aged 80 and over; Celiac Disease; Child; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Crohn Disease; Humans; Male; Microsatellite Instability; Middle Aged; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Tumor Suppressor Protein p53; Young Adult; Gastroenterologybusiness.industryTumour-infiltrating lymphocyteRisk FactorCancerMicrosatellite instabilityinflammatory bowel disease; microsatellite instability; MLH1 promoter methylation; tumour-infiltrating lymphocytes; survivalmedicine.diseaseSurvival Analysiseye diseasesdigestive system diseasesCeliac Disease030104 developmental biologyMicrosatellite instabilityTumor Suppressor Protein p53businessJournal of Crohn's and Colitis
researchProduct

Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases

2017

Background The expression of CD70 on T cells is greatly enhanced by antigen-presenting cell (APC)-associated signals, such as tumour necrosis factor(TNF)-α, which is constitutionally high in patients with inflammatory bowel disease (IBD). Experimentally, the chronic activation of CD27 as a result of the constitutive expression of CD70 leads to the demise of B cells in bone marrow (BM) and the secondary lymphoid organs. The aim of this study was to assess the number and phenotype of circulating B cell in untreated IBD patients and their counterparts treated with biological anti-TNF drugs. Methods The study involved 13 untreated IBD patients, 36 IBD patients treated with biological drugs, and…

Male0301 basic medicineT-LymphocytesImmunophenotypingB cell homeostasisBiological drugs; Inflammatory bowel diseases; Plasmablasts; TNF-αHomeostasisImmunology and AllergyCD20B-LymphocytesbiologyB-LymphocyteAntibodies MonoclonalMiddle AgedFlow Cytometrymedicine.anatomical_structureFemaleTumor necrosis factor alphaImmunotherapyAntibodyPlasmablastsHumanAdultAdolescentBiological drugImmunologyB-Lymphocyte SubsetsPlasmablastCD19ImmunophenotypingYoung Adult03 medical and health sciencesHomeostasimedicineHumansBiological drugsB cellB-Lymphocyte SubsetPharmacologyTumor Necrosis Factor-alphabusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseases030104 developmental biologyT-LymphocyteTNF-αImmunologybiology.proteinBone marrowbusinessCD27 LigandInternational Immunopharmacology
researchProduct

Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study

2011

International audience; AIM: To assess the effects and safety of Lactobacillus casei rhamnosus LCR35 complete freeze-dried culture (LCR35) in patients suffering from irritable bowel syndrome (IBS). METHODS: A randomized, double-blind pilot study was performed in 50 patients complaining of IBS symptoms complying with Rome III criteria. Patients were allocated to receive either LCR35 (n = 25) at a minimum daily dose of 6 × 10(8) colony forming units or placebo (n = 25) for 4 wk. At inclusion, after treatment and 2 wk later, patients completed the IBS severity scale. Change from baseline in the IBS severity score at the end of treatment was the primary efficacy criterion. Changes were compared…

MaleAbdominal painConstipationPilot ProjectsGastroenterologyIrritable Bowel Syndromefluids and secretions0302 clinical medicinescoreProspective StudiesProspective cohort studyDepression (differential diagnoses)Irritable bowel syndrome0303 health scienceseducation.field_of_studysignes et symptômes digestifsbiologyLacticaseibacillus rhamnosusdigestive oral and skin physiologyGastroenterologyfood and beveragesGeneral MedicineMiddle Agedprobiotique3. Good healthFemale030211 gastroenterology & hepatologymedicine.symptomAdultsyndrome de l'intestin irritablemedicine.medical_specialtyBrief ArticlePopulationPlacebolactobacillus rhamnosus03 medical and health sciencesDouble-Blind MethodLactobacillus rhamnosusInternal medicinemedicineHumanseducation030304 developmental biologybusiness.industryProbiotics[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologybiology.organism_classificationmedicine.diseaseSurgeryHépatologie et GastroentérologieFreeze DryingPatient ComplianceHépatology and Gastroenterologybusiness
researchProduct

Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last?

2009

Irritable bowel syndrome (IBS) is the most common functional digestive disorder, and may affect 11-20% of the adult population in industrialized countries. In accordance with Rome III criteria (2006) IBS involves abdominal pain and bowel habit disturbance, which are not explained by structural or biochemical abnormalities. Several hypotheses attempt to account for the pathophysiology of IBS, but the etiology still remains uncertain or obscure, perhaps multifactorial. Abnormalities in colonic microflora have recently been suggested in such patients, as has abnormal small-intestine bacterial overgrowth (SIBO), or in particular a significant reduction in the amount of intraluminal Bifidobacter…

MaleAbdominal painFunctional digestive disordersGastroenterologylaw.inventionIrritable Bowel SyndromeProbioticlawPrevalenceIntestinal MucosaIrritable bowel syndromeEnterocolitis PseudomembranousBifidobacteriumEnterocolitisClinical Trials as TopicTravelbiologyGastroenterologyGeneral MedicineIntestinesTreatment OutcomeFemalemedicine.symptomAdultDiarrheamedicine.medical_specialtyfunctional digestive disordersirritable bowel syndrome (ibs)mucosal associated microbiota (mam)Internal medicineDigestive disordermedicineIntestinal microfloraHumanslcsh:RC799-869intestinal microfloraMucosal associated microbiota (MAM)business.industryClostridioides difficileIrritable bowel syndrome (IBS)ProbioticsAbdominal distensionbiology.organism_classificationmedicine.diseaseLactobacillusSpainlcsh:Diseases of the digestive system. GastroenterologyBifidobacteriumFlatulencebusinessRevista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
researchProduct